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In human airways, extracellular adenosine regulates
epithelial functions supporting mucociliary clearance,
an important airway defense mechanism against bacte-
rial infection. Thus, defining the mechanisms of adeno-
sine generation is critical for elucidating the role of this
nucleoside in airway homeostasis. In this study, we
identified the source of adenosine on the mucosal sur-
face of human airway epithelia. Polarized primary cul-
tures of human nasal or bronchial epithelial cells were
assayed for transepithelial transport, cytosolic and cell
surface adenosine production. Ussing chamber experi-
ments indicated that serosal 1 M [3H]adenosine was not
transported to the mucosal compartment. Messenger
RNA for the cytosolic AMP-specific 5-nucleotidase
(CN-I) was not detected in human bronchial epithelial
cells, suggesting that mucosal adenosine did not origi-
nate from intracellular pools. In contrast, extracellular
0.1 mM ATP was rapidly dephosphorylated into adeno-
sine on the mucosal epithelial surface. We identified two
ectonucleotidases that mediated the conversion of AMP
to adenosine: ecto 5-nucleotidase (ecto 5-NT, CD73) and
alkaline phosphatase (AP). Both mucosal and serosal ep-
ithelial surfaces displayed ecto 5-NT activity (Km  14 M,
Vmax  0.5 nmolmin
1cm2), whereas AP activity was
restricted to the mucosal surface (Km,high  36 M, Vmax 
1.2 nmolmin1cm2; Km,low  717 M, Vmax  2.8 nmol
min1cm2). In bronchial cultures and tissues, ecto 5-NT
accounted for >80% of total activity toward 0.01 mM AMP,
compared with <15% for 5 mM AMP. The proximal airway
AP isoform was identified as nonspecific AP (NS AP) by
levamisole sensitivity and mRNA expression. The two ec-
toenzymes presented opposite airway distributions, ecto
5-NT and NS AP mRNA dominating in higher and lower
airways, respectively. Collectively, these experiments
support a major role for extracellular nucleotide catalysis
and for ecto 5-NT and NS AP in the regulation of adeno-
sine concentrations on airway surfaces.
Mucociliary clearance (MCC)1 constitutes an essential com-
ponent of airway defense against the development of infectious
lung diseases (1). Several epithelial functions involved in MCC
are regulated by extracellular nucleotides. For instance, P2Y2
receptor activation by ATP or UTP-stimulated Ca2-dependent
Cl channels (ICA) (2, 3), cilia beating frequency (CBF) (4, 5),
and mucin secretion from goblet cells and submucosal glands
(6, 7). Two members of the P2X receptor subfamily were re-
cently identified in human airway epithelial cultures: P2X4 and
P2X5 (8). These ATP-gated cationic channels increased Ca
2-
dependent Cl secretion (8) and CBF (9) in airway epithelia.
Interestingly, extracellular adenosine was found to be respon-
sible for regulating the post-peak sustained phase of increased
CBF induced by ATP on human nasal explants (4). In a human
bronchial cell line lacking P2Y2 receptors (Calu-3; Ref. 10), the
channel activity of the cystic fibrosis transmembrane regulator
was inhibited by 8-p-sulfophenyltheophylline, a nonspecific
blocker of cell surface adenosine receptors (11). Subsequently,
adenosine was shown to regulate CBF (4, 5) and ion transport
(12–15) through activation of cell surface A2B receptors.
The importance of adenosine receptor-mediated regulation of
MCC remains unclear because of the lack of information on
endogenous sources of extracellular adenosine on the mucosal
surface of airway epithelia. Adenosine could originate from the
interstitial compartment and penetrate airway epithelial tight
junctions to reach the lumen. The nucleoside could also be
generated intracellularly by the cytosolic AMP-specific 5-nu-
cleotidase (CN-I) (16, 17) and reach the mucosal surface
through nucleoside transporters (for review see Ref. 18). Alter-
natively, ATP release and cell surface conversion into adeno-
sine has been reported in numerous mammalian cells (19).
Human airway epithelial cells release ATP under basal condi-
tions (20, 21) and by mechanical stimulations such as mem-
brane stretch (22, 23), shear stress (24, 25), or hypotonicity-
induced swelling (26–28). All adenine nucleotides and
nucleosides have been detected in the airway surface liquid
under basal conditions (29). Lazarowski et al. (30) established
that cell surface adenine nucleotide and nucleoside concentra-
tions are maintained by a balance between ATP release and
cell surface metabolism.
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We recently demonstrated that exogenous ATP is dephos-
phorylated into ADP, AMP, and adenosine at the surface of
human nasal and bronchial epithelial cells (31). Two ectoen-
zymes have been reported to dephosphorylate AMP into aden-
osine on mammalian cells: ecto 5-nucleotidase (ecto 5-NT,
CD73, eN; EC 3.1.3.5; Ref. 32) and alkaline phosphatases (APs,
EC 3.1.3.1; Ref. 33). Whereas ecto 5-NT specifically dephos-
phorylates nucleoside monophosphates (AMP 3 adenosine
(32)), APs will metabolize a spectrum of substrates, including
5-nucleotides (ATP 3 ADP 3 AMP 3 adenosine), pyrophos-
phate, and p-nitrophenyl phosphate (33). The AP family con-
tains four ectoenzymes: intestinal AP (I AP), tissue nonspecific
AP detected in several organs including liver, bone, and kidney
(NS AP), placental AP (PLA AP), and germ-cell AP (G AP)
reported in testis and malignant tumors (34, 35). Two AP
isoforms have been localized in human airways: NS AP and
PLA AP. NS AP activity was detected by histochemistry on the
epithelial surface lining the entire respiratory system, except
for Type I pneumocytes (36), which express PLA AP (37). Bron-
choalveolar fluid AP activity has been used for decades to
diagnose acute lung injury and chronic disorders like idiopathic
pulmonary fibrosis (38, 39). Because bronchoalveolar fluid and
lung tissue AP activities are classically assayed with p-nitro-
phenyl phosphate as substrate (38–40), the possible role of
human airway AP in the production of extracellular adenosine
has not been investigated. Furthermore, ecto 5-NT activity has
not been investigated in human airways. Thus, the pharmaco-
logical manipulation of endogenous adenosine levels by target-
ing these ectoenzymes remains an unexplored area.
The purpose of this study was to identify the source(s) of
extracellular adenosine on the mucosal surface of human air-
way epithelia, distinguishing between permeation from the
interstitium, synthesis and secretion from the epithelial cells,
and/or cell surface metabolism of released nucleotides. All ex-
periments were performed on primary epithelial cultures,
freshly excised airway epithelia or bronchial sections. Serosal
to mucosal permeability was measured by Ussing chamber
experiments with [3H]adenosine, and the transported species
were identified by high-performance liquid chromatography
(HPLC). The expression of cytosolic CN-I was investigated by
reverse transcriptase-polymerase chain reaction (RT-PCR).
Based on our data suggesting that adenosine resulted from cell
surface conversion of ATP 3 ADP 3 AMP 3 adenosine (31),
we investigated in detail the biochemical properties and rela-
tive contribution of ecto 5-NT and APs. Enzyme expression
and tissue distribution were determined by RNase protection
assays (RPA). Because of the potential importance of adenosine
in diseases associated with airway inflammation (41), we in-
vestigated the impact of a prototypic inflammatory cytokine,
interleukin-1 (IL-1), on ecto 5-NT and APs expression.
EXPERIMENTAL PROCEDURES
Cell Culture—Well differentiated primary cultures of human nasal
and bronchial epithelial cells were grown as previously described (42).
In brief, cells were isolated from freshly excised nasal turbinate and
mainstem bronchi by protein digestion (43), and plated on porous
Transwell Col filters (well diameter, 12 mm; pore size, 0.45 M; Costar)
in air-liquid interface medium (50:50 mixture of LHC basal and Dul-
becco’s modified Eagle’s medium-H, 0.5 ng/ml epidermal growth factor,
50 nM retinoic acid, 0.5 mg/ml bovine serum albumin, 0.8% bovine
pituitary extract, 50 units/ml penicillin, and 50 g 47 l streptomycin)
(44). Once they reached confluence, the cultures were maintained at an
air-liquid interface with air-liquid interface medium added only to the
serosal compartment. After 4 weeks, the cultures were composed of
columnar ciliated cells (90%) and secretory cells, covering a layer of
basal-like cells (45). Enzyme assays were conducted on cultures of
transepithelial electrical resistance 300 /cm2. Lactate dehydrogen-
ase activity was employed as a test of cellular integrity.
Enzyme Assays on Epithelial Cultures—The epithelial cultures were
rinsed three times with Krebs buffer (KRB (in mM)), 140 Na, 120 Cl,
5.2 K, 25 HCO3
, 2.4 HPO4
, 1.6 Ca2, 1.6 Mg2, 5.2 glucose, and 25
HEPES (pH 7.4), and preincubated in KRB (0.35 ml mucosal/serosal)
for 30 min at 37 °C (5% CO2, 95% O2). Reactions were initiated with the
substrate (AMP, UMP, CMP, GMP, or IMP) dissolved in 35 l of KRB.
Aliquots (10 l) were collected over 10 to 60 min, boiled 3 min, filtered,
and analyzed by HPLC. For the determination of pH sensitivity,
HEPES was used to buffer solutions at pH 6.5 to 8.0, Tricine for
solutions at pH 8.0 and 8.5, and CHES for solutions at pH 8.5 and 9.0.
In these buffers, bicarbonate was omitted for better control of pH.
Ussing Chamber Experiments—Primary nasal epithelial cultures
grown on SnapwellsTM (Costar; Cambridge, MA) were mounted in mod-
ified Ussing chambers (Physiologic Instruments, San Diego, CA) with
an aperture of 1.0 cm2. The epithelium was bathed on each side with 5
ml of HEPES-free KBR (pH 7.4, 37 °C), circulated by gas lift with 95%
O2, 5% CO2. The voltage was clamped to 0 mV, except for 3-s pulses
(10 mV) every 60 s. Short-circuit current (Isc) and transepithelial
resistance were digitally recorded from the output of voltage clamp. The
permeability coefficients (Pcoeff) for adenosine and mannitol were meas-
ured. Mannitol Pcoeff was used as an index of paracellular permeability.
Following a 45-min preincubation period with [3H]adenosine (0.01 Ci/
l; 1 M) and [14C]mannitol (0.2 Ci/l) added to the serosal bath,
aliquots (500 l) were collected from the mucosal side (sink) every 30
min and replaced with 500 l of HEPES-free KBR. Every 60-min
interval, 50 l was collected from the serosal (source) side. [14C]Man-
nitol and [3H]adenosine in the source and sink buffer samples were
measured using a liquid scintillation counter (Beckman LS 6500 coun-
ter) and Pcoeffs calculations were calculated with the established equa-
tion: Pcoeff  (Q/t/SA), where Q/t is the steady-state rate of ap-
pearance of the tracer in the sink (cpm/s), S is the source radioactivity
(cpm/cm3), and A is the surface area (cm2) (46). The units of Pcoeff are
cm/s. Mucosal and serosal buffer samples were also analyzed for nucle-
oside and nucleobase composition by HPLC.
Identification of the AMP-hydrolyzing Enzymes—Three enzymes
could be responsible for the conversion of extracellular AMP into aden-
osine on human airway epithelial surfaces: cytosolic 5-NT, ecto 5-NT,
and AP. The possible contribution of each enzyme was evaluated with
specific substrates and inhibitors. The non-hydrolyzable analog of ADP,
,-methylene ADP (,-met-ADP), inhibits ecto 5-NT and AP, but not
cytosolic 5-NT (32). Hence, complete inhibition of AMP hydrolysis by
,-met-ADP would rule out the contribution of released cytosolic 5-
NT. Ecto 5-NT activity was identified with concanavalin A, a plant
lectin that binds specifically to -D-glucosyl and -D-mannosyl residues
of glycoproteins (47). Concanavalin A has been reported to completely
inhibit the activity of ecto 5-NT, without affecting AP (48). The AP
activity was measured with a specific substrate (-glycerophosphate)
and inhibitor (levamisole). The substrate reports the biochemical activ-
ity of all AP isoforms (49), whereas levamisole sensitivity discriminates
between NS AP, PLA AP, and I AP (50). The identity of the AP iso-
form(s) was further addressed with L-phenylalanine (I AP and PLA AP)
and L-leucine (G AP) (34, 35). All experiments were conducted as de-
scribed above for enzyme assays. Reactions were initiated with -glyc-
erophosphate mixed with AMP. Alternatively, the cultures were prein-
cubated 20 min with an inhibitor (,-met-ADP, levamisole, amino
acids, or concanavalin A) before the onset of the reaction.
Kinetic Analysis of AMP Hydrolysis—All assays were conducted on
the mucosal surface of human bronchial epithelial cultures with
[3H]AMP (0.1 mCi; 1–3000 M), as described above for enzyme assays.
Samples were collected after incubation periods that limited substrate
hydrolysis to 10%, and were analyzed by HPLC. Kinetic parameters
for ecto 5-NT and AP were determined in the presence 10 mM levami-
sole and 5 mM concanavalin A, respectively. Michaelis constants (Km)
and maximal velocities (Vmax) were obtained from the slope and the
ordinate of Woolf-Augustinson Hoftsee transformations, respectively.
Catalytic efficiency (Cateff) was calculated from the velocity (Vo) at Km
divided by Km (51).
Competition studies were conducted to determine whether ADP
and/or ATP inhibited the hydrolysis of nucleoside monophosphates.
Because ecto 5-NT (48) and AP (33) hydrolyze AMP and UMP at
similar rates, UMP was chosen over AMP as substrate for two reasons:
1) to rule out interference from the adenylate kinase activity (ATP 
AMP 7 2ADP) we recently detected on these cells (52) and 2) to
distinguish substrates from inhibitors and their metabolites on the
HPLC chromatograms. Because we recently demonstrated that ATP
and ADP are hydrolyzed into AMP on these cells (31), the protocol was
designed to prevent interference of UMP hydrolysis by AMP produced
from ATP and ADP hydrolysis. Reactions were started with previously
mixed UMP (10, 30, or 100 M) and ATP or ADP (10, 30, 60, or 100 M).
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Samples were collected after incubation periods that limited AMP pro-
duction from ATP and ADP to 	0.1 M. These conditions also limited
ATP conversion into ADP to 10%. Inhibition patterns and constants
(Ki) were derived from Dixon plots.
Tissue Measurements of Enzyme Activities—The epithelial surface of
human bronchial sections was assayed for AMP hydrolysis by ecto
5-NT and NS AP. From each tissue sample, three circular pieces
(diameter, 12 mm) were assayed in parallel with 5 mM AMP. Each piece
was inserted into a 12-mm porous Transwell and sealed along the edges
with silicone. Epithelial surfaces were rinsed three times with KRB and
preincubated in KRB (0.35 ml of mucosal/serosal) for 30 min at 37 °C
(5% CO2, 95% O2). Reactions were initiated with the substrate dissolved
in 35 l of KRB. Five aliquots (10 l) were collected over 10–30 min,
boiled 3 min, filtered, and analyzed by HPLC. All three pieces were
submitted to a second set of experiments. Surfaces were rinsed and
tissues were preincubated 30 min at 37 °C (5% CO2, 95% O2) in KRB
(0.35 ml of mucosal/serosal) containing 10 mM levamisole, 5 mM con-
canavalin A or vehicle. Reactions were conducted as in the first set of
experiments. Ecto 5-NT and NS AP activities were calculated from the
differences in the rate of AMP hydrolysis between control and treated
experiments conducted on the same piece of tissue. The piece assayed
twice with 5 mM AMP in the absence of enzyme inhibitor provided a
control for tissue integrity. This protocol was repeated on different sets
of tissues with 0.01 mM AMP and 0.1 mM AMP. At the end of the
experiments, all sections were fixed and counterstained with hematox-
ylin and eosin (H&E) for light microscopic examination of the epithe-
lium. A Nikon microphot SA microscope connected to a 3CC-Chilled
Camera (Sony, Marietta, GA) and interfaced to a powerMac 8100 were
used to capture the images via Adobe Photoshop.
HPLC Analysis—All samples were analyzed by reversed-phase
paired-ion HPLC. The separation system consisted of a Dinamax C-18
column and a mobile phase developed with buffer A (10 mM KH2PO4
and 8 mM TBASH, pH 5.3) from 0 to 10 min, buffer B (100 mM KH2PO4,
8 mM TBASH, and 15% MeOH, pH 5.3) from 10 to 20 min, and buffer A
from 20 to 30 min. Absorbance was monitored at 254 nm with an on-line
model 490 multiwavelength detector (Shimadzu Science Instruments
Inc., Kyoto, Japan), and radioactivity was determined on-line with a
Flo-One Radiomatic  detector (Packard Instrument Co.).
Exposure of Human Airway Epithelia to IL-1—Primary cultures of
human bronchial epithelial cells were incubated during 24 h at 37 °C
(5% CO2, 95% O2) with a range of IL-1 concentrations reported to
induce the cyclooxygenase pathway (0.0–1.0 ng/ml) of human airway
epithelial cells (53). Because polarized airway cultures respond to pro-
longed (12 h) mucosal flooding by an increased acid production (54),
the cytokine was added to air-liquid interface medium in the serosal
bath. At the end of the challenges, the cultures were processed for total
RNA extraction and RPA analysis of enzyme expression.
Reverse Transcriptase-Polymerase Chain Reaction—Total RNA was
extracted from primary cultures and freshly excised human airway
epithelial cells, as previously described (55). Oligonucleotide primers
were generated from the sequence of human ecto 5-NT (CD73), cyto-
solic AMP-specific 5-nucleotidase (CN-I), and the four AP isoforms
(Table I). First strand cDNA was synthesized by RT reaction with 8 g
of total RNA and the outer antisense (AS2) primer, in a 20-l reaction
containing 10 mM dNTPs, 0.1 mM dithiothreitol, 40 units of RNase
inhibitor, and 400 units of Superscript II RT in supplied buffer (Invitro-
gen). The reaction was allowed to proceed for 1 h at 42 °C and stopped
by heating at 70 °C for 10 min. The cDNA was amplified by PCR with
the inner antisense (AS1) and the sense (S) primers by the “hot start”
technique: 36 cycles (1 min at 94 °C, 2 min at 57 °C, 3 min at 72 °C),
followed by 10 min at 72 °C. In the case of CN-I, the AS primer was
poly(dT) (16) and the PCR product mixture contained glyceraldehyde-
3-phosphate dehydrogenase primers (BD Biosciences) as internal con-
trol. The PCR was run in the presence of 2.5% Me2SO in the following
conditions: 35–55 cycles (1 min at 94 °C, 50 s at 45 °C, 25 s at 72 °C),
followed by 10 min at 72 °C. The amplified PCR products were gel
purified on 1% agarose gel for ecto 5-NT and APs, 1.5% agarose gel for
CN-I and glyceraldehyde-3-phosphate dehydrogenase (Qiagen gel puri-
fication kit). The PCR products were ligated by TA cloning into the
pCRII vector (Invitrogen) and the ligations transformed in One-Shot
cells (Invitrogen). Plasmid DNA from individual colonies was purified
with a commercial kit (Qiagen) and screened by automatic sequencing
to confirm the identity of the product, verify the absence of mutations,
and determine the orientation of the insert in the vector. All PCR
products were confirmed to be in 100% homology with the reported
human cDNA sequences. RT-PCR reactions conducted with RNA in the
absence of Superscript II RT yielded no signal on the gels, ruling out the
possibility of RNA contamination by genomic DNA.
RNase Protection Assays—Plasmids containing cDNA fragments for
human ecto 5-NT and NS AP were linearized with EcoRV. [32P]CTP-
labeled antisense probes were transcribed from the plasmid SP6 pro-
moter site, according to the manufacturer’s recommendations (MAXIs-
cript in vitro transcription kit; Ambion, Austin, TX). The housekeeping
gene probe -actin was prepared at low specific activity by adding 2 l
of 1 mM cold CTP to the labeling mixture and reducing the 32P label to
10 Ci per reaction. The probes were purified by electrophoresis on
RNase-free 5% acrylamide, 8 M urea gels (250 volts, 1 h), eluted and
hybridized (8 
 104 disintegration/min) with 20 g of total RNA (RPA
III kit; Ambion). The protected fragments were separated by electro-
phoresis on 5% acrylamide, 8 M urea gels (250 volts, 1 h). The gels were
dried on a vacuum dryer (60 °C, 4 h) and exposed to a storage phos-
phorscreen (Amersham Biosciences) for 4–8 days. The screen was
scanned with an optical scanner (Storm; Amersham Biosciences) and
the signals quantified using digital image analyzing software (Image-
Quant; Amersham Biosciences). Appropriate sense strand and yeast
RNA controls yielded no signal on the gels.
Statistical Analysis—All experiments were performed on cultures
and tissues from at least three donors. Rates of hydrolysis were calcu-
lated from the decrease in the amount of substrate monitored by HPLC,
and presented as nanomolesmin1cm2 of surface area. The values
were expressed as mean  S.E. Unpaired Student’s t tests were used to
assess the significance between means. Paired Student’s t tests were
used when comparing hydrolysis rates measured on the mucosal and
serosal surfaces of the same culture. Linear regressions, curve fits, and
TABLE I
Specific primers for the human ecto 5-NT alkaline phosphatases, and CN-1
Gene Accessionnumber Strand
a Sequence Position Fragmentsize
bp
5-NT NM 002526 S GGC GCC GAG GTG GCG CAC TTC ATG AAC GCC 341 587
AS1 GGA GTG TCC TCC CAC CAC GAC GTC CAC ACC 781
AS2 CTC GAT CTT CAG ATA GCC TAG GTA TTT GCC 928
NS AP NM 000478 S TGG AAC ATG AGT TAA CAT CTG ACC ACT GCC 300 640
AS1 TAC CAG TCC CGG TCA GCC GAG TGG GCG TAG 960
AS2 CTG ATG TTA TGC ATG AGC TGG TAG GCG ATG 1038
PLA AP NM 001632 S CTC CAG ACA TGC TGG GGC CCT GCA TGC TGC 56 691
AS1 TCT GAG CTC TTC TCT GGG GCA GAC ACG GAG 747
AS2 CTT GGC CCG ATT CAC CAC GGA GAT GAC CTC 1314
I APb NM 001631 S CCT CCC TGA TGG AGA TGA CAG AGG CTG CCC 2151 582
AS1 CGG GAG GCG CCA GGT CGC AGG CCG TGT AGG 3150
AS2 CAA CTG GGT GCG CGG CGT CGG TGG TGC AGG 3180
G AP J03252 S GAC TGC TTC CAG ACA TGC AGG GGC CCT GGG 436 693
AS1 CTT GGC CCG ATT CAC CAC GGA GAT GAC CTC 930
AS2 CTG AGC TCT TCT CTG GGG CAG ACA AAC AAG 1129
CN-I NM 032526 S TGG TTG TGT CCC AGA GTC AG 596 183
AS1 CTA CCC AGT GCC TCC AGA AA 757
a S, sense strand; AS1, inner antisense strand; AS2, outer antisense strand.
b Genomic DNA, fragment size without intron: 582 bp.
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data transformations were performed with the computer programs
Origin and Sigma plot.
Materials—All 5-nucleotides and adenosine were purchased from
Roche Molecular Biochemicals (Mannheim, Germany). Concanavalin A,
erythro-9-[2-hydroxyl-3-nonyl]adenine, -glycerophosphate, levami-
sole, L-phenylalanine, L-leucine, ,-met-ADP, EDTA, KH2PO4,
TBASH, Tricine, CHES, and HEPES were obtained from Sigma. HPLC
grade water was purchased from Fisher Scientific (Pittsburgh, PA). Cell
culture media, bovine serum albumin, bovine pituitary extract, epider-
mal growth factor, gentamicin, penicillin, retinoic acid, and streptomy-
cin were bought from Invitrogen and human cytokine IL-1 (rhIL-1)
from R&D Systems. [3H]Adenosine (20 Ci/mmol) and [3H]AMP (10
mCi/mmol) were obtained from Amersham Biosciences, D-[1-14C]man-
nitol (0.1 mCi/mmol) and [-32P]CTP (10 mCi/mmol) were from
PerkinElmer Life Sciences. Salts and solvents were of analytical grade.
RESULTS
Adenosine Accumulation on the Apical Surface of Human
Airway Epithelia—First, we explored the possibility that sero-
sal adenosine could reach the mucosal surface. Ussing chamber
experiments were performed on polarized cultures of human
nasal epithelial cells. When [3H]adenosine (0.01 Ci/l; 1 M)
was added to the serosal bath, tritiated compounds accumu-
lated in the mucosal bath with a significantly higher Pcoeff than
for [14C]mannitol (Fig. 1A). However, HPLC analysis of the
tritiated species revealed that serosal [3H]adenosine was con-
verted into [3H]inosine and [3H]hypoxanthine within 30 min in
the serosal compartment (Fig. 1B). The only radiolabeled mol-
ecule detected on the mucosal surface over 30 min was [3H]hy-
poxanthine. These results suggest that interstitial fluid does
not constitute a source of adenosine for the mucosal surface of
airway epithelia.
We then tested whether adenosine could be generated within
the cytosol of columnar epithelial cells and released onto the
mucosal surface. To evaluate this possibility, we performed
RT-PCR experiments for the expression of CN-I (16, 17). Ex-
periments performed with total RNA from human heart or
human embryonic kidney cells (HEK 293) produced a positive
band of expected size for CN-I (Fig. 1C), as previously reported
(16). In contrast, no reaction product was obtained with total
RNA from freshly excised human bronchial epithelial cells or
human placenta (negative control; Ref. 16), even after 55 PCR
cycles (not shown). These experiments indicated that extracel-
lular adenosine, detected on the mucosal surface of human
airway epithelia does not originate from intracellular
compartments.
Numerous cell types have the ability to release ATP (56) and
to transform the nucleotide into adenosine by cell surface en-
zymes (19). Because human airway epithelial cells were re-
ported to release ATP (20–28) and to accumulate all adenine
nucleotides on the mucosal surface (ATP, ADP, AMP) (29), we
tested whether extracellular adenosine could be generated
from mucosal cell surface nucleotide metabolism. Fig. 1D
shows that the mucosal surface of bronchial epithelial cultures
dephosphorylated 100 M ATP into ADP, AMP, and adenosine.
No nucleotide or nucleoside was detected in the opposite com-
partment, whether we administered ATP on the mucosal or
FIG. 1. Origin of extracellular aden-
osine on the mucosal surface of hu-
man airway epithelia. A and B, Ussing
chamber experiments on transepithelial
and paracellular adenosine transport.
[3H]Adenosine (1 M) and the paracellu-
lar marker [14C]mannitol were added to
the serosal bath of polarized nasal epithe-
lial cultures. Buffer samples were col-
lected over 90 min to calculate [3H]ade-
nosine and [14C]mannitol Pcoeffs. A,
adenosine Pcoeff was higher than mannitol
Pcoeff. B, HPLC analysis of serosal and
mucosal buffer samples collected over 30
min. Serosal [3H]adenosine (ADO) was
metabolized into inosine (INO) and hy-
poxanthine (HP). Traces of HP (but not
ADO) were detected in the mucosal bath.
C, RT-PCR agarose gel indicating the ab-
sence of mRNA for cytosolic 5-nucleotid-
ase (CN-I). Lane 1, human placenta RNA
(negative control; 16); lane 2, human em-
bryonic kidney cells (HEK 293) overex-
pressing CN-I (positive control, 16); lane
3, human heart RNA (positive control)
(16); lanes 4 and 5, freshly excised bron-
chial epithelium from 2 donors. Glycer-
aldehyde-3-phosphate dehydrogenase
(GAPDH)-specific product of 983 bp was
produced by all reactions (internal con-
trol). D, production of adenosine from
ATP. On the mucosal surface of human
bronchial epithelial cells 0.1 mM ATP was
dephosphorylated into ADP, AMP, and
ADO. No substrate or product was de-
tected on the serosal surface, and vice
versa (data not shown). Values represent
mean  S.E. of five to seven independent
experiments. *, p 	 0.01.
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serosal surface. These results were consistent with the data
showing that adenosine does not permeate through tight junc-
tions (see above).
Because these experiments indicated that adenosine accu-
mulated in the mucosal compartment primarily because of
extracellular ATP hydrolysis, we investigated the identity and
polarity of the ectoenzyme(s) responsible for the conversion of
extracellular AMP into adenosine on human airway epithelial
surfaces. The mucosal surface of human bronchial epithelial
cultures metabolized 0.1 mM AMP with a half-life of 15 min
(Fig. 2A). The nucleotide was converted into adenosine, inosine,
and hypoxanthine (Fig. 2A). The adenosine deaminase inhibi-
tor, 10 M erythro-9-[2-hydroxyl-3-nonyl]adenine (57), pre-
vented the accumulation of inosine and hypoxanthine (data not
shown), supporting cell surface generation from adenosine. The
properties of AMP hydrolysis on airway epithelial surfaces
corresponded to those of membrane-bound ectonucleotidases
for the following reasons. First, the substrate was hydrolyzed
by intact cells and the product was released into the buffer (Fig.
2B). Second, AMP hydrolysis followed a linear relationship
over time on both epithelial surfaces (Fig. 2B), making it un-
likely that a significant amount of the substrate had been
hydrolyzed after entering the cells and products released in the
ectodomain. Third, KRB buffer conditioned by a 60-min expo-
sure to mucosal or serosal surfaces hydrolyzed 0.1 mM AMP at
rates that corresponded to 	5% of total cell surface activity
(Fig. 2B). Collectively, these experiments demonstrate that
membrane-bound ectoenzymes are responsible for adenosine
production at the surface of human airway epithelia.
The AMP hydrolytic activity measured on human bronchial
epithelial cells was also detected with epithelial cultures de-
rived from human nasal turbinate (Fig. 2C). Hydrolysis rates
were 2–3-fold higher on bronchial than on nasal cultures. In
addition, both cell types exhibited enzyme activities that were
3–5-fold higher on the mucosal surface than on the serosal
surface. These results suggest that the conversion of extracel-
lular AMP into adenosine occurs throughout airways, and that
this activity predominates on the epithelia surface facing the
airway lumen.
Biochemical Properties of AMP Hydrolysis—Human bronchial
epithelial cells were examined for their substrate specificity, di-
valent cation, and pH sensitivity. The cultures displayed broad
substrate specificity for nucleoside monophosphates. On the
mucosal surface, hydrolysis rates were in the following order:
AMP  UMP  CMP  GMP  IMP (Fig. 3A). Mucosal
AMPase activity was not affected by Ca2, but was signifi-
cantly increased by Mg2 (Fig. 3B). Hydrolytic rates were 30%
higher in buffers containing 3 mM Mg2 or 3 mM Mg2 and 3
mM Ca2 than with 3 mM Ca2 alone (Table II). Assays con-
ducted on the serosal surface were not influenced by the buffer
composition in divalent cations (Table II). The pH dependence
profile of mucosal AMP hydrolysis followed a bimodal pattern,
with optimal pH around 7.5 and 9.0 (Fig. 3C). Serosal AMPase
activity produced a single activity peak at pH 7.5. The fact that
mucosal and serosal surfaces displayed different cation and pH
sensitivities suggested the presence of more than one AMP-
hydrolyzing enzyme on human airway epithelial surfaces.
Identification of the Ectoenzymes—We investigated the iden-
tity of the enzymes responsible for AMP hydrolysis on human
bronchial epithelial surfaces under physiological conditions
(pH 7.4). The non-hydrolyzable analog of ADP, ,-met-ADP,
has been described as a competitive inhibitor of ecto 5-NT and
AP that has no effect on cytosolic 5-NT (32). Fig. 4A shows that
,-met-ADP inhibited the hydrolysis of 0.1 mM AMP in a
concentration-dependent manner on both epithelial surfaces.
AMP hydrolysis was completely abolished by 0.1 mM ,-met-
ADP, which ruled out the contribution of released cytosolic
5-NT. This finding is in agreement with the absence of mRNA
for CN-I (Fig. 1C).
Two types of ectonucleotidases could be involved in the me-
tabolism of extracellular AMP: ecto 5-NT (32) and APs (33).
Their activity at the surface of human bronchial epithelial cells
FIG. 2. Characterization of cell sur-
face adenosine production. A, HPLC
analysis for the conversion of extracellu-
lar AMP into adenosine. Mucosal 0.1 mM
AMP was converted into adenosine
(ADO), inosine (INO), and hypoxanthine
(HP) on bronchial cultures. B, AMP-hy-
drolyzing ectoenzymes are cell-associ-
ated. The mucosal surface ( ) hydrolyzed
AMP at higher rates than the serosal (f)
surface. KRB conditioned during 60 min
on the mucosal (E) or serosal () surface
hydrolyzed 0.1 mM AMP at 	5% of total
AMPase activity. C, AMP hydrolysis on
nasal and bronchial epithelial cells. Mu-
cosal activities (filled bars) were 3-fold
higher than serosal activities (open bars).
Reaction rates were higher on bronchial
cultures. Values represent mean  S.E. of
4–12 independent experiments. *, p 	
0.05; **, p 	 0.01.
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was detected with concanavalin A (48) and -glycerophosphate
(49), respectively. Dose-response curves were constructed with
5 mM AMP and various inhibitor concentrations. On the muco-
sal surface, both compounds reduced the rate of AMP hydrol-
ysis in a saturable manner (Fig. 4B). Concanavalin A inhibited
21  4% of total AMPase activity, with an IC50 of 9.0 M. In
contrast, -glycerophosphate reduced AMP hydrolysis by 84 
5%, with an IC50 of 26 M. Similar results were obtained when
-glycerophosphate was replaced by levamisole. This non-com-
petitive AP inhibitor reduced the rate of AMP hydrolysis by
81  3%, with an IC50 of 17 M (Fig. 4B). Based on IC50 values
reported for levamisole on NS AP (30 M), PLA AP (1.7 mM),
and I AP (6.8 mM) (50), the AP isoform expressed on human
bronchial epithelial cells is likely to be NS AP. The identity of
the AP isoforms expressed in human airways was further ad-
dressed with specific amino acids. The rate of AMP hydrolysis
was not significantly reduced by 10 mM L-phenylalanine (PLA
AP and I AP inhibitor) or by 10 mM L-leucine (G AP inhibitor)
(34, 35), respectively (data not shown). Collectively, these ex-
periments indicate that ecto 5-NT and NS AP are responsible
for the production of adenosine on human airway epithelial
cells.
The polarity of ecto 5-NT and NS AP on human bronchial
epithelial cultures was addressed with concentrations of con-
canavalin A (5 mM) and levamisole (10 mM) that produced
maximal inhibition (Fig. 4B). With 0.1 mM AMP, levamisole
and concanavalin A reduced mucosal rates of hydrolysis by
23  3 and 78  5%, respectively (Fig. 4C). The two enzymes
added together completely abolished AMP hydrolysis. On the
serosal surface, levamisole had no significant effect on AMP
hydrolysis, whereas concanavalin A completely inhibited the
reaction. These results indicate that ecto 5-NT was expressed
on both mucosal and serosal surfaces, whereas NS AP activity
was restricted to the mucosal surface. The relative contribution
of the two enzymes on mucosal surfaces was strongly influ-
enced by substrate concentration. Assays conducted with 5 mM
AMP generated total activities 5 times higher than with 0.1 mM
substrate. Under these conditions, levamisole and concanava-
TABLE II
Impact of divalent cations on AMP hydrolysis by mucosal and serosal
surfaces of human bronchial epithelial cells
Assays were conducted with 0.1 mM AMP in the absence/presence of
3 mM Ca2 and/or 3 mM Mg2. Values represent means (S.E.) of four
experiments.
Buffer composition
(divalent cations) Mucosal % Serosal %
nmol min1 cm2 mol min1 cm2
None 1.18  0.04 100 0.74  0.04 100
Ca2 1.22  0.04 102 0.71  0.05 96
Mg2 1.54  0.05 131a 0.76  0.04 103
Ca2 and Mg2 1.59  0.05 134a 0.79  0.03 106
a Values significantly different from rates obtained with buffer devoid
of divalent cation (p 	 0.05, Student’s paired t test).
FIG. 3. Biochemical properties of AMP hydrolysis by human
bronchial epithelial cells. A, substrate specificity. The mucosal sur-
face was assayed with 0.1 mM nucleoside monophosphate in KRB, and
buffer aliquots were analyzed by HPLC. All substrates were hydro-
lyzed: AMP (A)  UMP (U)  CMP (C)  GMP (G)  IMP (I). B, cation
sensitivity. Assays were performed on the mucosal surface with 0.1 mM
AMP in KRB containing various concentrations of Ca2 (E) or Mg2 ( ).
The reaction was insensitive to Ca2 and stimulated by Mg2. C, pH
dependence. The profile for 0.1 mM AMP was bimodal on the mucosal
surface ( ), with a single peak on the serosal surface (f). Values
represent mean  S.E. of three to five independent experiments. *,
p 	 0.05.
FIG. 4. Identification of the AMP-hydrolyzing ectoenzymes on
human bronchial epithelial cells. A, concentration-dependent inhi-
bition of AMP hydrolysis by ,-met-ADP. Reactions were initiated
with 0.1 mM AMP and 0, 0.01, or 0.1 mM ,-met-ADP in KRB on
mucosal (filled bars) and serosal (open bars) surfaces, and buffer ali-
quots were analyzed by HPLC. B, detection of mucosal ecto 5-NT and
AP activities. Reaction rates for 5 mM AMP decreased with increasing
concentrations of concanavalin A ( ), -glycerophosphate (f), or le-
vamisole (). C and D, polarity of ecto 5-NT and AP. On the mucosal
surface, levamisole (L) and concanavalin A (C) reduced reaction rates by
23  3 and 78  5% with 0.1 mM AMP (C) and by 83  4 and 28  3%
with 5 mM AMP (D). Serosal reactions (C and D) were insensitive to
levamisole and completely inhibited by concanavalin A. The two inhib-
itors together (LC) abolished the reactions on both surfaces. Values
represent mean  S.E. of four to seven independent experiments. *,
p 	 0.05.
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lin A reduced mucosal rates of AMP hydrolysis by 83  4 and
28  3%, respectively (Fig. 4D). Whereas ecto 5-NT activity
was already maximal with 0.1 mM AMP, NS AP activity was 5
times higher with 5 mM AMP. These results suggested distinct
kinetic properties for the two AMP-hydrolyzing enzymes.
Kinetic Properties of the AMP-hydrolyzing Enzymes—The
kinetic properties of AMP hydrolysis were examined on the
mucosal surface of human bronchial epithelial cultures. Fig. 5A
shows that the rate of AMP hydrolysis decreased with increas-
ing substrate concentration. Hydrolytic rates did not saturate
with millimolar AMP, suggesting the presence of at least two
catalytic sites with different substrate affinities.
The profile was not significantly modified when ecto 5-NT
activity was inhibited by 5 mM concanavalin A (Fig. 5A), sug-
gesting that AP activity dominated at high AMP concentra-
tions, as shown in Fig. 4D. Woolf-Augustinson Hoftsee trans-
formation revealed two kinetic components for AP: a high
affinity and a low affinity activity. The Km and Vmax values of
the high affinity activity were 36  8 M and 1.2  0.2 nmol
min1cm2, respectively (Fig. 5A, inset). The Km and Vmax
values of the low affinity activity were 717  49 M and 2.8 
1.2 nmolmin1cm2, respectively. The Cateff of the high affin-
ity activity was 4-fold higher than the Cateff of the low affinity
activity, with 0.021  0.005 min1 and 0.006  0.001 min1,
respectively.
Experiments conducted in the presence of the AP inhibitor
(10 mM levamisole) revealed a simple Michaelis-Menten equa-
tion for the ecto 5-NT reaction rate reaching saturation around
1 mM AMP (Fig. 5B). Woolf-Augustinson Hoftsee transforma-
tion indicated a single high affinity activity, with Km and Vmax
values of 14  3 M and 0.52  0.05 nmolmin1cm2, respec-
tively (Fig. 5B, inset). Calculated Cateff was 0.041  0.006
min1, which is 2-fold higher than the value obtained for the
high affinity AP activity.
We investigated the impact of ATP and ADP on the hydrol-
ysis of nucleoside monophosphates by human bronchial epithe-
lial cells. The assays were conducted with UMP instead of AMP
to distinguish the substrate from the inhibitors and their me-
tabolites on the HPLC chromatograms (see “Experimental Pro-
cedures”). The rate of UMP hydrolysis was inversely related to
ATP and ADP concentrations. Dixon plot analysis indicated a
competitive pattern of inhibition for both ADP (Fig. 5C) and
ATP (Fig. 5D), with Ki values of 7 and 10 M, respectively.
These results suggest that extracellular ATP and ADP partic-
ipate in the control of adenosine concentrations on human
airway epithelial cells.
Tissue Measurements of Ecto 5-NT and NS AP—The rela-
tive contributions of ecto 5-NT and NS AP activities to AMP
hydrolysis were examined on the epithelial surface of freshly
excised bronchial sections. Fig. 6A shows that the polarized
cultures closely reproduced the in vivo morphologic character-
istics displayed by freshly excised bronchial epithelia. Both
preparations exhibited a layer of columnar ciliated and secre-
tory epithelial cells covering cuboidal basal-like cells. The epi-
thelial surface of the bronchial sections was assayed with 0.01–
5.0 mM AMP, in the absence/presence of the ecto 5-NT (5 mM
concanavalin) or NS AP (10 mM levamisole) inhibitor (see “Ex-
perimental Procedures”). Ecto 5-NT activity was 5-fold higher
than NS AP activity when assayed with 0.01 mM AMP (Fig.
6B). In contrast, NS AP activity dominated with 0.1 and 5 mM
AMP. These results are in agreement with the cell culture
model (Fig. 4, C and D), suggesting that the two AMP-hydro-
lyzing enzymes address distinct pools of nucleotides on human
airway epithelial surfaces.
Expression of Ecto 5-NT and NS AP in Cultured and Excised
Epithelia—The identity of the AP isoforms expressed on hu-
man airway epithelial cells was addressed by RT-PCR with
primers specific for NS AP, PLA AP, I AP, and G AP (Table I).
These experiments were performed with total RNA extracted
from primary cultures of human nasal, bronchial, and bron-
chiolar epithelial cells. Control reactions were conducted with
commercial human total RNA (BD Biosciences): liver (NS AP),
FIG. 5. Kinetic analysis of ecto
5-NT and NS AP activities on human
bronchial epithelial cells. A, properties
of NS AP. Reactions initiated with
0.001–3 mM [3H]AMP in the absence (- - -)
or presence (—) of 5 mM concanavalin A.
Inset, Woolf-Augustinson Hoftsee trans-
formation fitted to two regressions (r 
0.96–0.99), with Km, Vmax, and Cateff of
717  49 M, 2.8  1.2 nmolmin1cm2,
and 0.006  0.001 min1, and 6  8 M,
1.2  0.2 nmolmin1cm2, and 0.021 
0.005 min1, respectively. B, properties of
ecto 5-NT. Reactions initiated with
0.001–3 mM [3H]AMP and 10 mM levami-
sole. Inset, Woolf-Augustinson Hoftsee
transformation fitted to a single regres-
sion (r  0.99), with Km, Vmax, and Cateff
of 14  3 M, 0.52  0.05 nmol
min1cm2, and 0.041  0.006 min1, re-
spectively (n  6; S.E. 	 5% of the mean).
C and D, impact of ADP and ATP on UMP
hydrolysis. Reactions initiated with UMP
10 M ( ), 30 M (f), or 100 M (Œ) and
ADP (10, 30, 60, or 100 M) or ATP (10,
30, 60, or 100 M). Buffer aliquots were
analyzed by HPLC. Dixon plots showed
(C) ADP and (D) ATP as competitive in-
hibitors of UMP hydrolysis, with correla-
tion coefficients of 0.96–0.99. Values rep-
resent mean  S.E. of five independent
experiments.
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small intestine (I AP), placenta (PLA AP), and testis (G AP)
(35). Only two AP isoforms were detected in human airway
epithelial cells: NS AP and PLA AP. Agarose gels exhibited
strong mRNA signals for NS AP in all epithelial samples (Fig.
7A). In contrast, PLA AP was not detected in nasal and bron-
chial epithelial cells and produced a weak signal in bronchiolar
epithelial cells. These results are consistent with the inhibition
data indicating that the AP activity, detected on bronchial
epithelial surfaces, corresponded to the NS AP isoform (Fig.
4B). Similar results were obtained for RT-PCR performed with
total RNA from freshly excised human airway epithelia (data
not shown).
The co-expression of ecto 5-NT and NS AP in primary cul-
tures of human nasal and bronchial epithelial cells was con-
firmed by RPA. Both enzymes displayed mRNA levels that
were 2–3 times higher in bronchial than in nasal epithelial
cells (Fig. 7B), findings consistent with the biochemical meas-
ures of their relative cell surface AMPase activities (Fig. 2C).
Impact of Environmental Conditions on Adenosine Produc-
tion—Because the airways are continuously exposed to inhaled
bacteria, we investigated whether the aseptic and stable envi-
ronment provided by the cell culture conditions affected the
expression of ecto 5-NT and NS AP. Fig. 8A shows that ecto
5-NT mRNA levels in epithelial cultures and freshly excised
bronchial epithelia were not significantly different. In contrast,
NS AP mRNA was 10-fold lower in culture (p 	 0.01). These
results suggest that the contribution of NS AP to adenosine
production in human airways would be underestimated by ex-
periments performed on epithelial cultures. To further test this
notion, we compared the mRNA levels of ecto 5-NT and NS AP
in human epithelia freshly excised from the nose, trachea, bron-
chi, and bronchioles. Fig. 8B shows that the two ectoenzymes
were detected throughout the respiratory tract. Ecto 5-NT and
NS AP were expressed at comparable levels in nasal turbinate
and tracheal epithelia. In lower airways, ecto 5-NT expression
gradually decreased toward alveoli, whereas NS AP mRNA in-
creased with airway generation. These results, combined with
the ex vivo assays conducted on bronchial sections (Fig. 6B),
support a major role for NS AP in the elimination of high ( 0.01
mM) nucleotide concentrations below the tracheobronchial tree.
We also tested the impact of the inflammatory mediator IL-
on the expression of ecto 5-NT and NS AP. Primary cultures of
human bronchial epithelial cells were exposed to serosal 0.1–
1.0 ng/ml IL-1 in air-liquid interface medium during 24 h and
then processed for RPA. Fig. 9 shows that NS AP mRNA
increased with IL-1 concentration, whereas ecto 5-NT mRNA
was unaffected. Collectively, these two sets of experiments
FIG. 6. Tissue measurements of ecto 5-NT and NS AP activi-
ties. A, typical brightfield (H&E) sections of human airway epithelium
from freshly excised main bronchus and polarized bronchial cultures. B,
AMP hydrolysis on the epithelial surface of bronchus sections. Mucosal
NS AP (filled bars) and ecto 5-NT (open bars) activities toward 0.01–5
mM AMP assayed with 5 mM concanavalin A and 10 mM levamisole,
respectively. Values represent mean  S.E. of four independent exper-
iments. *, p 	 0.05.
FIG. 7. Expression of ecto 5-NT and
NS AP in primary cultures of human
airway epithelial cells. A, identifica-
tion of the AP isoform by RT-PCR. Reac-
tions conducted with total RNA from cul-
tured airway epithelial cells and primers
for NS AP, I AP, PLA AP, and G AP (Ta-
ble I). Controls: commercial human RNA
(BD Biosciences) from liver (NS AP),
small intestine (I AP), placenta (PLA AP),
and testis (G AP). B, co-expression of ecto
5NT and NS AP detected by RPA in nasal
and bronchial cultures. The mRNA levels,
normalized with -actin, were 2–3 times
lower in nasal (N, filled bars) than bron-
chial (B, open bars) epithelial cells. Val-
ues corrected for the number of G-C bind-
ing sites represent mean  S.E. of three
independent experiments. *, p 	 0.05.
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suggest that the high affinity ecto 5-NT modulates physiolog-
ical nucleotide concentrations, independently of the environ-
mental conditions. In contrast, the fact that NS AP was down-
regulated in cell culture, but up-regulated by IL-1, suggests
that the ectoenzyme could be recruited by inflammatory medi-
ators released on epithelial surfaces in response to infection.
DISCUSSION
The current understanding of airway defense mechanisms
against bacterial infection acknowledges a complex interplay
between ATP and adenosine receptor-mediated epithelial func-
tions (2–15). However, despite numerous studies demonstrat-
ing that ATP is released from the mucosal surface of human
airway epithelia (20–28), the origin of extracellular adenosine
has not been established. In the present work, we considered
three possible sources of adenosine for the mucosal surface: 1)
paracellular or transepithelial transport from the interstitium;
2) cytosolic formation and release from epithelial cells facing
the lumen; and 3) cell surface metabolism of locally released
ATP. First, Ussing chamber experiments demonstrated that
serosal [3H]adenosine did not permeate into the mucosal com-
partment, but was locally converted into [3H]inosine and
[3H]hypoxanthine (Fig. 1, A and B). This observation was con-
firmed by applying ATP to the serosal compartment and
searching by HPLC for the appearance of purine nucleotides/
nucleosides on the mucosal surface (Fig. 1D). Second, we pro-
vided evidence that adenosine was not generated intracellu-
larly for transport to the mucosal surface. Specifically, we
sought evidence for the mRNA encoding the cytosolic enzyme
for adenosine production, CN-I (16, 17), and no evidence for
expression of this transcript was found by RT-PCR (Fig. 1C).
Moreover, we recently reported that extracellular adenosine
was actively removed from the mucosal surface of human nasal
epithelial cultures by a concentrative Na-dependent nucleo-
side transporter (58). These properties are consistent with the
vectorial transport system described for adenosine across in-
testinal epithelia (59, 60). Taken together, these findings indi-
cate that interstitial and cytosolic pools of nucleosides do not
contribute to the endogenous adenosine concentrations de-
tected on the mucosal surface of human airway epithelia (29).
The abundant literature describing basal and stimulated
ATP release from the mucosal surface of airway epithelia (20–
FIG. 9. Impact of IL-1 on the expression of human airway ecto
5-NT and NS AP. Primary cultures of human bronchial epithelial cells
were exposed to serosal 0.0–1.0 ng/ml IL-1 during 24 h. RPAs on total
RNA showed that NS AP (open bars), but not ecto 5-NT (filled bars),
was up-regulated by IL-1. Values normalized with -actin and cor-
rected for the number of G-C-binding sites represent mean  S.E. of
three independent experiments. *, p 	 0.05.
FIG. 8. Cell culture versus tissue ex-
pression of ecto 5-NT and NS AP. A,
selective down-regulation by the culture
conditions. RPAs conducted with total
RNA from freshly excised (F, filled bars)
and cultured (C, open bars) human bron-
chial epithelial cells. NS AP (but not ecto
5-NT) mRNA was higher in vivo than in
culture. B, opposite distributions for ecto
5-NT (filled bars) and NS AP (open bars)
in human airways. RPAs conducted with
total RNA from freshly excised human
nasal, tracheal, bronchial, and bronchio-
lar epithelial cells. Values normalized
with -actin and corrected for the number
of G-C binding sites represent mean 
S.E. of four independent experiments. *,
p 	 0.05.
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28) raised the possibility that released ATP could represent the
major source of adenosine through cell surface metabolism.
Indeed, cell surface conversion of extracellular ATP into aden-
osine has been reported in most mammalian tissues (19). In the
present study, we have shown that ATP is sequentially dephos-
phorylated into ADP, AMP, and adenosine on airway epithelial
surfaces. The physiological importance of constitutive ATP re-
lease and conversion to adenosine was emphasized by the sub-
stantial inhibitory effect (70%) of 0.3 mM ,-met-ADP on the
basal cystic fibrosis transmembrane regulator activity of
Calu-3 cells (11). This compound has been described as a com-
petitive inhibitor of ecto 5-NT and AP, preventing cell surface
conversion of AMP to adenosine (32). The fact that ATP, ADP,
AMP, and adenosine were confined to the epithelial surface on
which ATP was administered suggested that mucosal and se-
rosal surfaces represent distinct compartments with respect to
nucleotide pools and purine-mediated signaling pathways.
Patch clamp studies on Calu-3 cells demonstrated the close
proximity between the site of ATP release, the enzymes respon-
sible for adenosine production, A2B receptors, G proteins, and
cystic fibrosis transmembrane regulator (11). Taken together,
these findings support local ATP release and metabolism as the
major source of adenosine for P1 receptor activation on the
mucosal surface of human airway epithelia.
The present work identifies the ectoenzymes directly respon-
sible for the production of adenosine from AMP on the mucosal
surface of human airway epithelia. The conversion of extracel-
lular AMP into adenosine was detected on nasal and bronchial
epithelial cells, suggesting widespread expression throughout
human airways. Several ectoenzymes have been reported to
dephosphorylate AMP in the ectodomain: ecto 5-NT and APs.
The biochemical properties of AMP hydrolysis on primary cul-
tures of human bronchial epithelial cells supported the func-
tional expression of more than one ectoenzyme. Mucosal sur-
faces hydrolyzed nucleoside monophosphates with a substrate
specificity (AMP  UMP  CMP  GMP  IMP) intermediate
between that of purified ecto 5-NT (AMP  UMP  CMP 
GMP  IMP (48)) and purified AP (AMP  UMP  CMP 
GMP  IMP (33)). Mammalian ecto 5-NT and AP have been
reported to display different cation and pH sensitivities. Puri-
fied ecto 5-NT from rat glioblastoma was insensitive to Ca2
and Mg2 (47). In contrast, human liver AP (61) and kidney AP
(62) activities were enhanced 2–3-fold by Mg2, suggesting that
an AP could be responsible for the Mg2-sensitive AMPase
activity we detected on the mucosal surface of human bronchial
epithelial cells (Fig. 3B). In the presence of Mg2, the optimum
pH of purified ecto 5-NT and AP were reported in the range
7.5–8.0 (47, 63) and 9–10 (33, 61, 62), respectively. We showed
that assays conducted in the presence of Ca2 and Mg2 gen-
erated two peaks of activity (pH 7.5 and 9.0) on the mucosal
surface and a single peak (pH 7.5) on the serosal surface (Fig.
3C). Bimodal pH dependence profiles (pH 8.0 and 10.0) were
also reported for AMPase activities measured on intact cells or
plasma membrane preparations, the alkaline peak of activity
exhibiting an absolute requirement for Mg2 (64, 65). Collec-
tively, these results suggest that ecto 5-NT was responsible for
the activity peak detected on both surfaces around pH 7.5,
whereas the alkaline activity restricted to the mucosal surface
corresponded to APs.
The identity of the AMP-hydrolyzing enzymes expressed on
human bronchial epithelial cells at pH 7.4 was further inves-
tigated with specific inhibitors. The activity of ecto 5-NT was
revealed with concanavalin A, a lectin reported to have no
effect on APs (48). When reactions were initiated with 0.1 mM
AMP, this compound inhibited 80 and 100% of total activity
measured on mucosal and serosal surfaces, respectively. The
remaining mucosal AMPase activity was completely inhibited
by -glycerophosphate and levamisole, non-competitive (49)
and competitive (50) inhibitors of APs, respectively. Con-
versely, serosal AMP hydrolysis was insensitive to levamisole.
These results were in agreement with the polarity of ecto 5-NT
and AP activities suggested by the pH and cation sensitivity
experiments.
Levamisole has been used to discriminate between NS AP
(IC50  30 M), PLA AP (IC50  1.7 mM), and I AP (IC50  6.8
mM) (50). The high sensitivity of the mucosal AMPase activity
to levamisole (IC50  17 M; Fig. 4B) suggests that NS AP
would be the major AP isoform expressed on human airway
epithelial cells. In addition, the reaction was resistant to 10 mM
L-phenylalanine (PLA and I AP inhibitor) and 10 mM L-leucine
(G AP inhibitor) (34, 35). This identification of NS AP as the
dominant AP isoform expressed in proximal airways was con-
sistent with mRNA expression studies. Two AP isoforms were
detected by RT-PCR in total RNA extracted from cultured or
freshly excised human nasal, bronchial, and bronchiolar epi-
thelial cells: NS AP and PLA AP (Fig. 7A). Whereas strong
signals were obtained for NS AP in all RNA fractions, PLA AP
mRNA was limited to bronchiolar epithelial cells. The localiza-
tion of NS AP and PLA AP in human lungs has been investi-
gated by histochemical and immunocytochemical procedures
(36, 37). L-p-Bromotetramisole-sensitive L-phenylalanine-re-
sistant NS AP activity was detected on the epithelial surface
lining the entire respiratory system (36). In contrast, PLA AP
distribution was restricted to peripheral lung parenchyma: res-
piratory bronchioli, alveolar ducts, alveolar sacs, and alveoli
(37). Therefore, the identity of the human airway AP isoforms
provided in this work by functional assays and RT-PCR was
supported by studies of their tissue distribution.
The polarized primary cultures of human nasal and bron-
chial epithelial cells exhibited the in vivo morphologic charac-
teristics of proximal airway epithelia (45), with columnar cili-
ated and secretory cells covering basal-like cells. Based on the
biochemical properties of AMP hydrolysis on these cells, ecto
5-NT would be expressed on mucosal and serosal surfaces of
airway epithelia, whereas NS AP would be restricted to the
mucosal surface. In rat nasal respiratory epithelium, ecto
5-NT displayed a polarity consistent with these results (66).
Ecto 5-NT was localized by histochemistry to the mucosal
surface of columnar epithelial cells and the underlining basal
cells. Human airway NS AP was detected predominantly on the
apical plasma membrane of columnar epithelial cells (36).
These in vivo studies support the polarity we obtained for ecto
5-NT and NS AP activities on the culture model.
Novel information on the tissue distribution of the AMP-
hydrolyzing ectoenzymes was provided by quantitative analy-
sis of mRNA levels throughout human airways with cultured
and freshly excised epithelial preparations. First, ecto 5-NT
and NS AP expression were 2–3 times higher in bronchial than
in nasal epithelial cultures. Second, we demonstrated with
freshly excised epithelial cells that the two ectoenzymes exhibit
opposite expression patterns throughout airways. Ecto 5-NT
mRNA levels gradually declined from nasal to bronchiolar ep-
ithelia, whereas the expression of NS AP increased with airway
generation. This constitutes the first report of ecto 5-NT in
mammalian airway epithelia below the nasal cavity. Interest-
ingly, opposite gradient distributions for the two ectoenzymes
were also reported for mammalian intestinal mucosa, with
decreasing ecto 5-NT immunostaining (67) and increasing AP
activity (68) from the small intestine to the colon.
The relative contribution of the two AMP-hydrolyzing ec-
toenzymes on the mucosal surface of human bronchial epithe-
lial cells was strongly influenced by substrate concentration.
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Experiments conducted on epithelial cultures (Fig. 4, C and D)
and freshly excised bronchial tissues (Fig. 6B) indicated that 5
mM AMP was eliminated 5–6 times more rapidly by NS AP
than by ecto 5-NT. In contrast, ecto 5-NT activity dominated
5-fold over NS AP when assayed with 10 M AMP (Fig. 6B).
Further analysis of the substrate concentration-enzyme activ-
ity relationship revealed different kinetic properties for the two
ectoenzymes (Fig. 5, A and B). Ecto 5-NT presented a single
high affinity activity for AMP, with a Km of 14 M, a value that
falls within the range reported for purified ecto 5-NT (5–20
M) (47, 63). In contrast, NS AP exhibited two kinetic compo-
nents: a high affinity (Km  36 M) and a low affinity (Km  717
M) activity. These findings are consistent with the kinetic
properties reported for NS AP purified from rat osseous plates
at pH 7.5, with Km values of 82 M and 1.3 mM for ATP (69).
Human osteosarcoma NS AP assayed at pH 7.4 also displayed
high and low affinity activities, with Km values of 25 and 780
M, respectively (51). The fact that ecto 5-NT and NS AP
possess high affinity activities suggests that they both partic-
ipate in the metabolism of nucleotide concentrations (10 M)
detected locally following ATP release from human airway
epithelial cells (70–72). However, the 2-fold higher Cateff of
ecto 5-NT predicts that this enzyme would be more efficient
than NS AP at producing adenosine from physiological AMP
concentrations, as demonstrated by their respective contribu-
tion to the hydrolysis of 10 M AMP on bronchial cultures and
tissues. Finally, AMP hydrolysis was competitively inhibited
by ATP (Ki  7 M) and ADP (Ki  10 M) on human bronchial
epithelial cells (Fig. 5, C and D), as previously reported for
purified rat renal ecto 5-NT (Ki  0.03–30 M) (63, 73, 74).
Consequently, the conversion of AMP into adenosine would
represent a rate-limiting step in the production of P1 receptor
agonists from ATP release on airway surfaces.
The purinergic modulation of MCC on human airway epithe-
lial surfaces involves a complex interplay between nucleotide
and nucleoside concentrations, ectonucleotidases, P2 and P1
receptors. Mechanical stimulation, such as coughing-induced
shear stress, raises local cell surface ATP to concentrations
(1–10 M) (70–72) that initiate P2 receptor-mediated MCC
functions (2–9). Desensitization of the P2Y2 receptors by pro-
longed exposure to micromolar nucleotides (4, 75) might be
avoided by the rapid dephosphorylation of ATP and ADP into
AMP we reported on human airway epithelial surfaces (21, 31).
Through the conversion of extracellular AMP into adenosine,
ecto 5-NT and NS AP would provide the agonist (adenosine)
required for the smaller but more sustained MCC responses,
mediated by A2B receptor regulation of CBF (4, 5) and ion
transport (12–15).
In summary, we have demonstrated that ecto 5-NT and NS
AP are responsible for the production of adenosine on the
mucosal surface of human airway epithelial cells. The rela-
tively high efficiency of ecto 5-NT suggests that this enzyme
would play a major role in the regulation of adenosine-medi-
ated epithelial functions. On the other hand, all APs dephos-
phorylate not only AMP but also ADP and ATP (33). Under
pathological conditions, trauma generates quantities of extra-
cellular nucleotides that may cause damage to the epithelium.
For example, airway epithelial cultures have been reported to
express P2X7 receptors (8), an ATP-gated channel known to
induce apoptosis (76). The high-capacity NS AP could protect
these airways against the deleterious effects of high ATP con-
centrations. The fact that IL-1 enhanced 5-fold NS AP activity
and expression supports a role for this enzyme in airway de-
fenses during periods of inflammation. We would note, how-
ever, that the broad substrate specificity of APs suggests that
NS AP could be involved in other airway functions, including
bacterial endotoxin neutralization (77) and sphingosine 1-phos-
phate receptor signaling (78, 79).
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